High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey

Shin Ono 1,2, Takuro Sugai 2,3, Yutaro Suzuki 2,3, Manabu Yamazaki 4, Kazutaka Shimoda 2,5, Takao Mori 4, Yuji Ozeki 2,5, Hiroshi Matsuda 6, Norio Sugawara 6, Norio Yasui-Furukori 2,6, Kurefu Okamoto 6, Toyoaki Sagae 7 and Toshiyuki Someya 2,3*

Abstract

Background: Patients with schizophrenia have an increased prevalence of metabolic disturbances compared with the general population. However, the mechanisms underlying the metabolic side effects of antipsychotics are unknown. The aim of the present study was to compare the levels of high-density lipoprotein (HDL)-cholesterol in Japanese schizophrenia patients medicated with olanzapine, risperidone, or aripiprazole monotherapy.

Methods: This study was a post-hoc analysis of a nationwide survey, which included 433 Japanese outpatients with schizophrenia and 674 inpatients. A brief questionnaire was compiled that covered demographic data, systolic blood pressure, diastolic blood pressure, and HDL-cholesterol after reviewing the relevant literature and guidelines. To compare demographic and clinical characteristics, analysis of variance was performed for continuous variables and the chi-square test was performed for categorical variables. For comparisons of HDL-cholesterol levels among the three antipsychotic groups, analysis of covariance was carried out with age, diastolic blood pressure, chlorpromazine-equivalent dosage, and waist circumference as confounding variables after stratification by body mass index (BMI) for each outpatient group and inpatient group.

Results: The mean age was 57.9 ± 14.0 years and the mean BMI was 23.4 ± 4.5 kg/m². HDL-cholesterol levels when stratified by BMI differed significantly (p = 0.019) between the three antipsychotic groups after age, diastolic blood pressure, chlorpromazine-equivalent dosage, and waist circumference in inpatients. A significant difference in HDL-cholesterol levels was only found in the overweight inpatient group, and no significant differences in HDL-cholesterol levels were found among the three antipsychotics for outpatients of all BMI stratifications or inpatients that were underweight or of normal weight. For post-hoc analysis of HDL-cholesterol levels in overweight inpatients, HDL-cholesterol was significantly lower in the olanzapine group than in the aripiprazole group (p = 0.023).

Conclusions: This study reveals a difference in HDL-cholesterol levels in overweight Japanese inpatients resulting from the use of different antipsychotics. In the post-hoc analysis of HDL-cholesterol levels in overweight inpatients, HDL-cholesterol was significantly lower in the olanzapine group than in the aripiprazole group. Further studies incorporating more detailed evaluations, including diet and physical activity, are needed to clarify the differences in HDL-cholesterol according to antipsychotic use.

Keywords: Schizophrenia, Antipsychotics, High-density lipoprotein-cholesterol, Metabolic syndrome
Background

Patients with schizophrenia suffer from increased morbidity and mortality compared with the general population and have a life expectancy that is approximately 20% shorter [1]. Patients with schizophrenia also have an increased prevalence of cardiometabolic risk factors such as obesity, diabetes type 2, hypertension, hyperglycemia, and dyslipidemia compared with the normal population [2–4]. Low high-density lipoprotein (HDL)-cholesterol level, a cardiometabolic risk factor, is strongly and inversely associated with the risk of coronary heart disease [5]. Some studies attributed metabolic disturbance in schizophrenia to poor patient lifestyle choices such as sedentary lifestyle, smoking, poor diet, prolonged stress, as well as use of antipsychotic drugs, and genetic susceptibility [6].

Metabolic disorders associated with atypical antipsychotic drugs include abnormalities of glucose metabolism such as insulin resistance, hyperglycemia, dyslipidemia and weight gain [7–11]. In a meta-analysis study of second-generation antipsychotics, olanzapine increased cholesterol levels to a level higher than that induced by aripiprazole, risperidone, or ziprasidone [12]. However, the underlying causal mechanisms of metabolic side effects with antipsychotics are unknown. Apart from the effects of antipsychotics related to lipid abnormalities, patients with schizophrenia who are antipsychotic drug-naïve, or drug-free, also have low levels of HDL-cholesterol and are at high risk for metabolic syndrome [13].

Many confounding factors affect HDL-cholesterol levels. It is well known that HDL-cholesterol levels are decreased in overweight subjects [14, 15], and there is a negative association with body mass index (BMI) and HDL-cholesterol [16]. Additionally, smoking decreased HDL-cholesterol [17] while exercise increased HDL-cholesterol [18, 19]. As these various factors (e.g. diet, exercise, smoking, obesity, antipsychotics, and schizophrenia) influence HDL-cholesterol, it seems prudent to investigate HDL-cholesterol in schizophrenia in relation to BMI.

The prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotics is higher than in the general population. In a previous nationwide survey on the prevalence of metabolic syndrome in the Japanese population, the prevalence in outpatients was approximately 3-fold higher than that in inpatients [20]. Japan has more psychiatric hospitals than other Organization for Economic Cooperation and Development (OECD) countries [21]. The average length of stay in psychiatric beds was 301.0 days according to surveys by the Ministry of Health, Labour and Welfare in Japan [22], and the length of stay in psychiatric beds in Japan was considered longer than that in other countries. The system for psychiatric treatment in Japan is different from other countries in terms of longer stay in psychiatric beds and higher number of psychiatric beds. Of note, there is a relatively uniform diet or exercise regime in a hospitalized environment compared with the outpatient environment in Japan. Drug adherence is also maintained in hospitals. Therefore, differences in medical care environments, such as hospitalization and outpatient treatment, should be taken into account when evaluating HDL-cholesterol in schizophrenic patients, especially in Japan.

The aim of the present study was to compare HDL-cholesterol levels between Japanese schizophrenia patients medicated with olanzapine, risperidone, or aripiprazole monotherapy as a post-hoc analysis of a previous nationwide survey.

Methods

Subjects

This study was a post-hoc analysis of a previous survey [20]. Of the 23,116 subjects in the original survey, only those receiving monotherapy with olanzapine, risperidone, or aripiprazole were included in the present study. The original sample included 7655 outpatients and 15,461 inpatients diagnosed with schizophrenia who had been taking the same antipsychotics. All of the subjects were diagnosed with schizophrenia based on International Statistical Classification of Diseases and Related Health Problems version 10 (ICD-10) or the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) [23, 24]. The study protocol and informed consent procedure were approved by the Ethics Committee of the Japan Psychiatric Hospitals Association. The investigation was carried out in accordance with the Declaration of Helsinki. Each participant gave written informed consent prior to all study procedures.

The number of Japanese patients with schizophrenia was 795,000, and the majority of these patients were treated in hospitals in the Japan Psychiatric Hospitals Association in an investigation conducted by the Ministry of Health, Labour and Welfare in 2008. For the aim of assisting patients with schizophrenia, a joint project with the cooperation of the Japanese Society of Clinical Neuropsychopharmacology and the Japan Psychiatric Hospitals Association was started in Japan in 2012.

A questionnaire survey was conducted between January 2012 and July 2014. Responses were obtained from 7655 outpatients and 15,461 inpatients in 520 facilities for outpatients and 247 facilities for inpatients belonging to the Japan Psychiatric Hospitals Association. We excluded patients aged under 20 years; patients whose sex, BMI, and HDL-cholesterol data were not recorded; and patients medicated with polypharmacy of antipsychotics or monotherapy with drugs other than olanzapine, risperidone, or aripiprazole. The final study population comprised 1107 individuals.
Assessments
A brief questionnaire was compiled to cover demographic data (age and sex), systolic blood pressure, diastolic blood pressure, and HDL-cholesterol after reviewing the relevant literature and guidelines. Body weight, height, and waist circumference were measured, and BMI was calculated by weight (kg)/height squared (m²). Blood pressure was measured twice with patients in a seated position after at least 5 min of rest, using a standard mercury sphygmomanometer. HDL-cholesterol was measured by standard analytical techniques.

Statistical analyses
Demographic and clinical variables are presented as the mean ± standard deviation (SD) or proportion. To compare demographic and clinical characteristics between the three antipsychotic groups, analysis of variance was performed for continuous variables and the chi-square test was performed for categorical variables. The threshold for significance was set at p < 0.05. SPSS Statistics 24 for Mac OS (IBM Japan, Tokyo, Japan) was used for statistical analyses. For comparisons of HDL-cholesterol levels among the three antipsychotic groups, analysis of covariance was carried out with age, diastolic blood pressure, chlorpromazine-equivalent dosage, and waist circumference as confounding variables after stratification by BMI (BMI < 18.5, underweight; 18.5 ≤ BMI < 25, normal weight; BMI ≥ 25, overweight) for each outpatient group and inpatient group. Post-hoc analyses were performed using the Bonferroni method.

Results
There were 433 outpatients and 674 inpatients with schizophrenia in this study. All were Japanese with a mean age of 57.9 ± 14.0 years and a mean BMI of 23.4 ± 4.5 kg/m². Table 1 summarizes the demographic and clinical characteristics of the entire study population (n = 1107). No significant intergroup differences were observed for sex, BMI, waist circumference, systolic blood pressure, or HDL-cholesterol. Significant differences were observed for age (p < 0.001), diastolic blood pressure (p = 0.025), and chlorpromazine-equivalent dosage of current atypical antipsychotics (p < 0.001). The HDL-cholesterol levels for overweight inpatients differed significantly among the three antipsychotic groups (p = 0.019) after adjustment for age, diastolic blood pressure, chlorpromazine-equivalent dosage, and waist circumference. For post-hoc analysis of HDL-cholesterol levels in overweight inpatients among the three antipsychotic groups, HDL-cholesterol was significantly lower in the olanzapine group than in the aripiprazole group (p = 0.023), and HDL-cholesterol levels were similar between the olanzapine and risperidone groups (p = 0.160). HDL-cholesterol levels in underweight and normal weight patients did not differ significantly (Table 2). No significant differences in HDL-cholesterol levels were found among the three antipsychotics for outpatients of all BMI stratifications (Table 3).

Discussion
This study reveals that overweight inpatients with schizophrenia treated with antipsychotics had significant differences in HDL-cholesterol after adjustment for age, diastolic blood pressure, chlorpromazine-equivalent dosage, and waist circumference. However, there was no difference in HDL-cholesterol among the antipsychotic treatments in the overall patient group, outpatients of all BMI stratifications or inpatients of normal weight and underweight. We believe this survey is the first large-scale questionnaire survey in Japan to show a difference in HDL-cholesterol levels between antipsychotics drugs by BMI stratification.

Regarding the effects of antipsychotics on cholesterol, antipsychotic treatments have been reported to be associated with increased total and low-density lipoprotein (LDL)-cholesterol as well as decreased HDL-cholesterol [10, 25]. In a previous 52-week comparison study of olanzapine and aripiprazole, olanzapine was associated with significantly greater weight gain than aripiprazole throughout the study [26]. The change in HDL-cholesterol from baseline was significantly lower in the olanzapine group than in the aripiprazole group at the 52-week end-point where weight gain related to the two drugs was highest [26]. Although this prospective study by Chrzanowski and colleagues [26] was methodologically different to our cross-sectional study, our results also show that HDL-cholesterol is lower in overweight inpatients in the olanzapine group than in the aripiprazole group. A 1-year observation study on first-episode drug-naïve patients revealed significant differences in HDL-cholesterol decreases between groups of patients who gained > 20% or < 20% of their baseline BMI at 1 year, and no significant difference in HDL-cholesterol between olanzapine- and risperidone-treated patients [27]. This finding is in accord with the lack of difference observed between olanzapine and risperidone in overweight inpatients in the present study.

In a randomized comparative study of aripiprazole and olanzapine, no group differences were observed in the proportions of patients with potentially clinically significant fasting HDL-cholesterol levels, because the weight gain at the study end-point was significantly greater with olanzapine than with aripiprazole [28]. The discrepancy with the present results may arise because there was no correction of HDL-cholesterol by baseline BMI, waist circumference, or weight change in their study. In a comparison between olanzapine and risperidone, the patients included across all groups were, on average, overweight with a mean BMI of > 25 kg/m² and
Olanzapine-treated patients had significantly lower HDL-cholesterol levels than risperidone-treated patients [29]. Because the authors could not analyze inpatients and outpatients separately, their findings may not be consistent with the results of the current study.

In a study on the acute metabolic effects of olanzapine in healthy volunteers, there was a significant decrease in HDL-cholesterol, in the absence of changes in total cholesterol and LDL-cholesterol [30]. The decrease in HDL-cholesterol within a short time period suggested a direct effect of antipsychotics on HDL-cholesterol. Birkenaes and colleagues reported that even after correction for BMI, low HDL-cholesterol was observed in patients treated with olanzapine and clozapine [31]. Similarly, Kang and colleagues showed significant differences in the prevalence of low HDL-cholesterol after adjustment for BMI among atypical antipsychotic groups [32]. There may also be differences between antipsychotics regarding the direct effects on HDL-cholesterol.

In the present study, differences in HDL-cholesterol among patients treated with antipsychotics were not detected in outpatients. Although no direct comparisons of inpatients with outpatients were made in this study, a previous study reported that hypcholesterolemia was higher in inpatients than in outpatients or the general population [33, 34]. There was a possibility that drug adherence was decreased in outpatients compared with inpatients, and thus the effects of antipsychotic drugs on HDL-cholesterol may have been decreased in outpatients. In hospitalized patients, their diet is controlled, and the proportion of obese patients is lower compared with outpatients. Therefore, in the hospitalization environment, where drug adherence and diet are controlled, it may be possible to detect differences between the effects of different antipsychotics, unlike in outpatient environments. It was also reported that the most likely improvement in the lipid profile induced by physical activity was an increase in HDL-cholesterol [35]. Because the physical activity of outpatients is likely to be higher than that of inpatients, the effects of antipsychotics on HDL-cholesterol may be masked by the influence of physical activity, which may improve HDL-cholesterol.

| Table 1 | Comparisons of demographic and clinical characteristics of patients in the three antipsychotic groups |
|---------|---------------------------------------------------------------|
| Olanzapine (N = 356) | Risperidone (N = 529) | Aripiprazole (N = 222) | p-value |
| Age years | 56.4 ± 14.0 | 60.2 ± 13.2 | 54.8 ± 15.2 | < 0.001 |
| Females (males) | 158 (198) | 243 (286) | 115 (107) | 0.201 |
| Outpatients (inpatients) | 138 (218) | 194 (335) | 101 (121) | 0.077 |
| BMI kg/m² | 23.2 ± 4.1 | 23.5 ± 4.5 | 23.5 ± 5.1 | 0.516 |
| Waist circumference cm | 84.0 ± 11.5 | 84.8 ± 11.7 | 83.4 ± 14.1 | 0.297 |
| Systolic blood pressure mmHg | 124.5 ± 18.9 | 122.7 ± 17.3 | 123.9 ± 19.1 | 0.355 |
| Diastolic blood pressure mmHg | 77.2 ± 12.3 | 75.0 ± 12.5 | 74.9 ± 13.0 | 0.025 |
| HDL-cholesterol mg/dL | 54.3 ± 18.6 | 55.4 ± 17.9 | 57.5 ± 17.9 | 0.126 |
| CP-equivalent dosage of current AAP mg | 516.1 ± 261.7 | 420.8 ± 273.4 | 402.1 ± 231.7 | < 0.001 |

Concomitant drugs
- Antidepressant 1 0 0
- Mood stabilizer 6 11 3
- Benzodiazepines 7 13 2
- Anticholinergic drug 0 9 0

Data are shown as the mean ± SD or number of subjects.

Analyses of covariance among the three antipsychotics were performed for HDL-cholesterol with age, diastolic blood pressure, chlorpromazine-equivalent dosage and waist circumference as confounding variables.

| Table 2 | Comparisons of HDL-cholesterol levels in the three antipsychotic groups with stratification by BMI for inpatients |
|---------|---------------------------------------------------------------|
| HDL-cholesterol mg/dL | < 18.5 | 18.5 ≤ < 25 | ≥ 25 |
| Olanzapine | 62.0 ± 20.3 (34) | 54.1 ± 21.5 (137) | 43.8 ± 12.3 (47) |
| Risperidone | 58.6 ± 15.8 (55) | 55.0 ± 16.2 (196) | 49.7 ± 15.0 (84) |
| Aripiprazole | 62.6 ± 21.6 (28) | 58.2 ± 15.8 (68) | 54.7 ± 16.8 (25) |
| p-value | 0.490 | 0.282 | 0.019 Olanzapine < Aripiprazole (0.023) |

Data are shown as the mean ± SD (number of subjects).

Analyses of covariance among the three antipsychotics were performed for HDL-cholesterol with age, diastolic blood pressure, chlorpromazine-equivalent dosage and waist circumference as confounding variables. Post-hoc analyses were performed by the Bonferroni method.

HDL high-density lipoprotein, BMI body mass index.
levels. Antipsychotics or physical activity may directly influence the decrease in HDL-cholesterol levels, and the differences seen between these antipsychotics may be caused by factors other than being overweight.

In the study of BMI status of hospitalized Japanese schizophrenia patients, underweight as well as obesity was a characteristic in schizophrenia inpatients compared with the general population [36]. Regarding the characteristics of underweight, a previous study showed that the prevalence of hypotriglyceridemia was significantly higher in the underweight group than in the normal weight group and overweight/obese schizophrenia inpatients [33]. In this study, we did not conduct a direct comparison of HDL-cholesterol levels between overweight, normal weight, and underweight groups. We also did not assess triglyceride levels in this study. Therefore, further studies including metabolic parameters such as triglycerides are necessary for the assessment of underweight patients with schizophrenia.

For overall patients, the olanzapine group had a statistically significant higher chlorpromazine-equivalent dosage compared with the two other groups in this study. The HDL-cholesterol levels for overweight inpatients differed significantly among the three antipsychotic groups after adjustment for chlorpromazine-equivalent dosage. Regarding the risk of metabolic syndrome in psychiatry inpatients, metabolic syndrome was associated with chlorpromazine-equivalent total daily doses, and specifically with clozapine, olanzapine, and quetiapine [37]. There was no consensus as to whether there was a dose-dependence on weight gain or metabolic effects [38].

This study reveals a difference in HDL-cholesterol in overweight Japanese inpatients with schizophrenia resulting from the use of different antipsychotics. Further studies incorporating more detailed evaluations including diet and physical activity, are needed to clarify the differences in HDL-cholesterol according to antipsychotic use.

Limitations
The present study had several limitations. First, the cross-sectional and antipsychotic treatments were not performed randomly, and thus bias in the antipsychotic prescriptions was not controlled. Second, the present analysis was a post-hoc analysis of a study that was not designed or powered to demonstrate differences between treatments, and thus the possibility of type II errors may remain. Third, comparisons with unmedicated schizophrenia patients or healthy controls could not be performed in this study. Fourth, we did not assess psychiatric symptoms or severity using the Brief Psychiatric Rating Scale, Positive and Negative Symptom Scale or Clinical Global Impressions in this study. Psychiatric symptoms might be related to body weight, physical activity, or antipsychotic drugs, so further study including the assessment of symptoms and severity is required.

Conclusions
This post-hoc study of a large questionnaire survey showed differences in HDL-cholesterol levels between different antipsychotic monotherapies in Japanese inpatients with schizophrenia. HDL-cholesterol was significantly lower in the olanzapine group than in the aripiprazole group in overweight inpatients. The difference was only revealed in overweight inpatients, and further study is needed to evaluate factors such as diet and physical activity to clarify the differences in HDL-cholesterol levels related to antipsychotic use.

**Data are shown as the mean ± SD (number of subjects)**

**Analyses of covariance among the three antipsychotic groups for HDL-cholesterol with age, diastolic blood pressure, chlorpromazine-equivalent dosage and waist circumference as confounding variables**

**Post-hoc analyses were performed by the Bonferroni method**

**HDL: high-density lipoprotein, BMI: body mass index**

| HDL-cholesterol | BMI < 18.5 | Olanzapine | Risperidone | Aripiprazole | p-value |
|-----------------|-----------|------------|-------------|--------------|---------|
| mg/dL           |           | 72.1 ± 18.7 (8) | 81.3 ± 30.4 (4) | 62.5 ± 3.4 (4) | 0.959   |
| BMI ≥ 18.5      |           | 57.6 ± 13.4 (69) | 61.4 ± 23.0 (96) | 60.7 ± 17.7 (45) | 0.442   |
| mg/dL           | 53.0 ± 15.6 (61) | 52.7 ± 15.8 (94) | 51.9 ± 18.4 (52) |              | 0.819   |

**Abbreviations**

BMI: Body mass index; DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision; HDL: High-density lipoprotein; ICD-10: International Statistical Classification of Diseases and Related Health Problems version 10; LDL: Low-density lipoprotein; OECD: Organization for Economic Cooperation and Development; SD: Standard deviations

**Acknowledgements**

We are grateful to the study participants and the facilities belonging to the Japan Psychiatric Hospitals Association that cooperated with this investigation. We would like to thank all of our coworkers for their contributions to the data collection and management. Wendy Brooks, PhD, from Edanz Group (https://www.edanzediting.com/) provided English language editing services for a draft of this manuscript.

**Funding**

This work was partially supported by Eisai Co. Ltd., Yoshitomi Pharmaceutical Industries, Dainippon Sumitomo Pharma Co. Ltd, Astellas Pharma Inc, Meiji Seika Pharma Co. Ltd., Eli Lilly Japan K.K., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline K.K., Jansen Pharmaceutical K.K., MSD K.K., Shionogi & Co. Ltd., Asahi Kasei Pharma Corp, Novartis Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., and Tsumura & Co. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Availability of data and materials
The raw data were analyzed at Niigata University Graduate School of Medical and Dental Sciences. Data will not be made available because it will be included in future studies of follow-up analyses.

Authors’ contributions
Conceptualization: SO, Tsugai, YS, YO, NS, NYF, TSomeya. Supervision: TSugai, YS, TSomeya. Investigation: SO, Tsugai, YS, YO, NS, NYF, KO, TSomeya. Formal analysis: SO, Tsugai. Methodology: SO, Tsugai, YO, NS, KO, TSomeya. Project administration: TSugai, YS, TSomeya. Visualization: SO, Tsugai, YS, TSomeya. Writing – original draft: SO, Tsugai, YS, TSomeya. Writing – review & editing: SO, Tsugai, YS, MY, KS, TM, YO, HM, NS, NYF, KO, TSomeya. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All participants provided written consent prior to all study procedures. This research was approved by the Ethics Committee of the Japan Psychiatric Hospitals Association, Tokyo, Japan, and conforms to the provisions of the Declaration of Helsinki.

Competing interests
Toshiyuki Someya has received research support or honoraria from Ashai Kasei Pharma Corp, Astellas Pharma Inc, Daiichi Sankyo Co. Ltd, Dainippon Sumitomo Pharma Co. Ltd, Eisai Co. Ltd, Eli Lilly Japan KK, GlaxoSmithKline KK, Janssen Pharmaceutical KK, Meiji Sekia Pharma Co. Ltd, Mitsubishi Tanabe Pharma Co. Ltd, Mocheda Pharmaceutical Co. Ltd, MSD KK, Otsuka Pharmaceutical Co. Ltd, Pfizer Japan Inc, Shinogi Co. Ltd, Tsumura & Co., and Yoshitomi Pharmaceutical Industries. Yutaro Suzuki has received research support or honoraria from Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Co. Ltd, and Otsuka Pharmaceutical Co. Ltd. Kazutaka Shimoda has received research support or honoraria from Daiichi Sankyo Co. Ltd, Dainippon Sumitomo Pharma Co. Ltd, Eli Lilly Japan KK, GlaxoSmithKline KK, Meiji Sekia Pharma Co. Ltd, Novartis Pharma KK, Otsuka Pharmaceutical Co. Ltd, Pfizer Japan Inc, Shinogi & Co. Ltd, Takeda Pharmaceutical Co. Ltd, Tsumura & Co, Yoshitomi Pharmaceutical Industries Ltd, Ashai Kasei Pharma Corporation, Astellas Pharma Inc, Janssen Pharmaceutical KK, Kowa Pharmaceutical Co. Ltd., Meiji Sekia Pharma Co, Mitsubishi Tanabe Pharma Corporation Ltd, MSD KK, Novartis Pharma KK, and Ono Pharmaceutical Co. Ltd. Norio Yasui-Furukori has received research support or honoraria from Astellas Pharma Inc, Dainippon Sumitomo Pharma Co Ltd, Eli Lilly Japan Kk, GlaxoSmithKline KK, Janssen Pharmaceutical KK, Meiji Sekia Pharma Co, Mocheda Pharmaceutical Co. Ltd, MSD KK, Otsuka Pharmaceutical Co. Ltd, Pfizer Japan Inc, Takeda Pharmaceutical Co. Ltd, and Yoshitomi Pharmaceutical Industries. Norio Sugawara has received grant or research support from a Grant-in-Aid for Young Scientists (B), Ministry of Education, Culture, Sports, Science and Technology, Japan Grant B, A Karori Memorial Fund for Medical Research Grant, and The Senshin Medical Research Foundation. Shin Ono has received grant or research support from the Hospitals Bureau Niigata Prefecture Government and a Grant-in-Aid for Scientific Research (C). There are no patents, products in development, or marketed products to declare. The other authors declare no potential conflicts of interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Community Psychiatric Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. 2Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. 3Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. 4Japan Psychiatric Hospital Association, Tokyo, Japan. 5Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Japan. 6Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, Japan. 7Department of Health and Nutrition, Yamagata Prefectural Yonezawa University of Nutrition Sciences Faculty of Health and Nutrition, Yonezawa, Japan.

Received: 20 December 2017 Accepted: 23 May 2018
Published online: 08 June 2018

References
1. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.
2. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903–12.
3. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19–32.
4. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009;119:14–4.
5. Chovrov DF, Fedirko V, Cui Y, Szazovon V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16:404–23.
6. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15–22.
7. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.
8. Melkerson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64:701–23.
9. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:36–46.
10. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93.
11. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatr. 2006;51:480–91.
12. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123:225–33.
13. Enez Dacin A, Yalcin Cavus S, Dilbaz N, Kaya H, Dogan E. Metabolic syndrome in drug-naive and drug-free patients with schizophrenia and in their siblings. Schizophr Res. 2015;166:201–6.
14. Althink MJ, Krauss RW, Lindgren FT, von der Groeben H, Pan S, Wood PD. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids. 1980;15(9):668–76.
15. Wilson DE, Lees RS. Metabolic relationships among the plasma lipoproteins. Reciprocal changes in the concentrations of very low and low density lipoproteins in man. J Clin Invest. 1975;55:1051–7.
16. Shamai L, Lurix E, Shen M, Novaro GM, Szomstein S, Rosenthal R, et al. Association of body mass index and lipid profiles: evaluation of a broad spectrum of body mass index patients including the morbidly obese. Obes Surg. 2011;21(1):42–7.
17. Phillips NR, Havel RJ, Kane JP. Levels and interrelationships of serum and lipoprotein cholesterol and triglycerides. Association with adiposity and the consumption of ethanol, tobacco, and beverages containing caffeine. Arteriosclerosis. 1981;1(1):13–24.
18. Wood PD, Haskell WL. The effect of exercise on plasma high density lipoproteins. Lipids. 1979;14(6):417–27.
19. Superko HR. Exercise and lipoprotein metabolism. J Cardiovasc Risk. 1995; 2(4):310–5.
20. Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, et al. Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia: a nationwide survey. Schizophr Res. 2016;171:168–73.
21. Organisation for Economic Cooperation and Development. OECD health statistics 2017.
22. Ministry of Health and Welfare. Summary of Static/Dynamic Surveys of Medical Institutions and Hospital Report 2010. Statistics and Information Department; Minister’s Secretariat, Ministry of Health and Welfare, Tokyo.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 2000. Text Revision
24. World Health Organization. International statistical classification of diseases and related health problems 10th revision. 2004.
25. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(Suppl 4):8–13.

26. Chrzanowski WK, Marcus RN, Torbeyns A, Nyillas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology. 2006;189:259–66.

27. Perez-Iglesias R, Mata I, Pelayo-Teran JM, Arnado JA, Garcia-Urzuetz MT, Berja A, et al. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophr Res. 2009;107:115–21.

28. Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009;65:510–7.

29. Wishing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wishing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856–65.

30. Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One. 2011;6:e22662.

31. Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 2008;28:132–7.

32. Kang SH, Lee JI. Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics. Psychiatry Investig. 2015;12:242–8.

33. Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Tsuneyama N, et al. High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia. Psychiatry Clin Neurosci. 2014;68(1):78–82.

34. Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, et al. High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey. PLoS One. 2016;11:e0166429.

35. Mann S, Breddie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med. 2014;44:211–21.

36. Inamura Y, Sagae T, Nakamachi K, Murayama N. Body mass index of inpatients with schizophrenia in Japan. Int J Psychiatry Med. 2012;44(2):171–81.

37. Centorrino F, Masters GA, Talamo A, Baldessarini RJ, Öngür D. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol. 2012;27(5):521–6.

38. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041–50.